Martin Hellriegel
Papers
2
Total Citations
117
H-Index
2
About
Dr. Martin Hellriegel is a leading figure in gynecologic oncology, with a focused expertise in borderline ovarian tumours (BOT). His major contributions stem from his pivotal role in the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study, one of the largest and most comprehensive analyses of BOT. Through this work, Dr. Hellriegel has fundamentally advanced our understanding of how patient age and surgical staging influence clinical outcomes. His landmark 2014 study, cited over 75 times, revealed critical age-dependent differences in BOT prognosis and characteristics, challenging one-size-fits-all treatment approaches. A subsequent 2014 analysis, with 42 citations, systematically dissected the prognostic impact of individual surgical staging procedures, providing evidence-based guidance for clinicians. By demonstrating that incomplete staging is a negative prognostic factor, his research has directly shaped surgical standards for BOT management. Dr. Hellriegel’s work, grounded in a robust dataset of 950 centrally-reviewed patients, has established key benchmarks for risk stratification in this rare tumor type, making him a highly cited authority whose findings continue to inform clinical decision-making and improve patient outcomes in gynecologic oncology.
Research Focus
Key Achievements
Top Papers
- 1
- 2